Beta-Thalassemia
Rare Disease·MeSH: beta-Thalassemia
Prevalence
0.5 / 100K
5 drugs in development·5 companies·5 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| reblozyl | ACCELERON PHARMA INC (XLRN) |
Phase 3(2)
Phase 2(1)
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| st-400 | Bioverativ Inc. (BIVV) |
Compare drugs
Frequently asked questions
How many drugs are in development for Beta-Thalassemia?
BioSniper tracks 5 drugs in development for Beta-Thalassemia across 5 companies.
How many clinical trials target Beta-Thalassemia?
There are 5 clinical trials targeting Beta-Thalassemia tracked by BioSniper.
What is the prevalence of Beta-Thalassemia?
The estimated prevalence of Beta-Thalassemia is approximately 0.5 per 100,000 population.
Deep-dive into Beta-Thalassemia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis